|
US 12,076,380 B2 |
|
| Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| Toni Weinschenk, Tuebingen (DE); Andrea Mahr, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); Phillip Mueller, Tuebingen (DE); Anita Wiebe, Tuebingen (DE); and Sarah Kutscher, Tuebingen (DE) |
| Assigned to Immatics Biotechnologies GmbH, (DE) |
| Filed by IMMATICS BIOTECHNOLOGIES GMBH, Tuebingen (DE) |
| Filed on Oct. 1, 2021, as Appl. No. 17/492,112. |
| Application 17/492,112 is a continuation of application No. 17/245,918, filed on Apr. 30, 2021. |
| Application 17/245,918 is a continuation of application No. 17/018,915, filed on Sep. 11, 2020, abandoned. |
| Application 17/018,915 is a continuation of application No. 16/915,308, filed on Jun. 29, 2020, abandoned. |
| Application 16/915,308 is a continuation of application No. 16/134,422, filed on Sep. 18, 2018, abandoned. |
| Application 16/134,422 is a continuation of application No. 15/357,757, filed on Nov. 21, 2016, abandoned. |
| Application 15/357,757 is a continuation of application No. 14/975,952, filed on Dec. 21, 2015, granted, now 10,064,926, issued on Sep. 4, 2018. |
| Claims priority of provisional application 62/096,165, filed on Dec. 23, 2014. |
| Claims priority of application No. 1423016 (GB), filed on Dec. 23, 2014; and application No. 1501017 (GB), filed on Jan. 21, 2015. |
| Prior Publication US 2022/0016227 A1, Jan. 20, 2022 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 38/04 (2006.01); C07K 7/00 (2006.01); C07K 7/06 (2006.01); C07K 14/435 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/18 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); A61K 35/12 (2015.01); A61K 51/10 (2006.01); C07K 7/08 (2006.01); G01N 33/68 (2006.01) |